La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Jazz Pharmaceuticals a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Jazz Pharmaceuticals..

Jazz Pharmaceuticals (NASDAQ:JAZZ) Azioni, Catena delle Opzioni

Jazz Pharmaceuticals

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals PLC

JAZZ PHARMACEUTICALS ORD

Bruce C Cozadd, Chairman &amp; CEO at Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>), disclosed an insider sell on November 5, according to a recent SEC filing.
What Happened: Cozadd's decision to sell 1,000 shares of Jazz Pharmaceuticals was revealed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001232524/000176558124000086//Archives/edgar/data/1232524/000176558124000086/0001765581-24-000086-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday. The total value of the sale is $110,840.
In the Wednesday's morning session, Jazz Pharmaceuticals's shares are currently trading at $108.82, experiencing a down of 0.54%.
<h3>Get to Know Jazz Pharmaceuticals Better</h3>
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
<h3>Jazz Pharmaceuticals's Economic Impact: An Analysis</h3>
Positive Revenue Trend: Examining Jazz Pharmaceuticals's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 6.95% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Exploring Profitability:
<ul>
<li>
Gross Margin: The company sets a benchmark with a high gross margin of 89.27%, reflecting superior cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Jazz Pharmaceuticals's EPS is below the industry average, signaling challenges in bottom-line performance with a current EPS of 2.68.
</li>
</ul>
Debt Management: With a below-average debt-to-equity ratio of 1.54, Jazz Pharmaceuticals adopts a prudent financial strategy, indicating a balanced approach to debt management.
Insights into Valuation Metrics:
<ul>
<li>
Price to Earnings (P/E) Ratio: The P/E ratio of 18.89 is lower than the industry average, implying a discounted valuation for Jazz Pharmaceuticals's stock.
</li>
<li>
Price to Sales (P/S) Ratio: With a P/S ratio of 2.0 below industry standards, the stock shows potential undervaluation, making it an appealing investment option for those focusing on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): At 8.8, Jazz Pharmaceuticals's EV/EBITDA ratio reflects a below-par valuation compared to industry averages signalling undervaluation
</li>
</ul>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Uncovering the Importance of Insider Activity</h3>
Emphasizing the importance of a comprehensive approach, considering insider transactions is valuable, but it's crucial to evaluate them in conjunction with other investment factors.
From a legal standpoint, the term "insider" pertains to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as outlined in Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and significant hedge funds. These insiders are mandated to inform the public of their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
A company insider's new purchase is a indicator of their positive anticipation for a rise in the stock.
While insider sells may not necessarily reflect a bearish view and can be motivated by various factors.
<h3>Understanding Crucial Transaction Codes</h3>
In the domain of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their focus to those taking place in the open market, as meticulously outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001232524">Check Out The Full List Of Jazz Pharmaceuticals's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Insider Trades

Trading Ideas

JAZZ

Insider Decision: Bruce C Cozadd Offloads $110K Worth Of Jazz Pharmaceuticals Stock

First presentation of top-line efficacy and safety results from the Phase 4 DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment) trial of adults with narcolepsy or idiopathic hypersomnia
For U.S. media and investors only
DUBLIN, Oct. 31, 2024 /PRNewswire/ --&nbsp;Jazz Pharmaceuticals plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) today announced that eight abstracts presenting data from across its sleep portfolio were featured at the 37th annual Psych Congress, held in Boston from October 29 through November 2, 2024. The data includes the top-line results of the Phase 4 DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment) trial, evaluating the effectiveness of low-sodium oxybate on key sleep outcomes in adults with narcolepsy or idiopathic hypersomnia (IH). Notably, these DUET data are the first to show prospective improvements on excessive daytime sleepiness (EDS), as well as key polysomnography (PSG) outcomes of sleep disruption, among adults with narcolepsy treated with Xywav&#xAE; (calcium, magnesium, potassium, and sodium oxybates) oral solution. Further, new DUET data evaluating nighttime Xywav treatment in adults with IH demonstrate clinical improvements on daytime symptoms, including sleep inertia measured by the Patient Global Impression of Change (PGIc).&nbsp;
The DUET trial is a Phase 4, prospective, single-arm, open-label study to assess the effect of Xywav treatment on EDS, polysomnography parameters, and functional outcomes in adults with narcolepsy or IH. Observed adverse events were consistent with the known safety profile of Xywav, with the most common including nausea, dizziness and headache.

Biotech

General

Jazz Pharmaceuticals Presents New Data At Psych Congress 2024 Confirming Xywav Oral Solution Treatment Benefits In Narcolepsy And Idiopathic Hypersomnia

With this ruling, the approval of LUMRYZ is upheld based on the FDA's determination that LUMRYZ is clinically superior to Jazz's twice-nightly oxybate products.
"We are pleased with the Court's ruling in favor of the FDA's clinical superiority determination for LUMRYZ in conjunction with final approval for use in adults with narcolepsy," the company said.

Legal

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

Avadel Pharmaceuticals Says US District Court Ruled In Favor Of FDA In Suit Brought By Jazz Pharmaceuticals Under Administrative Procedure Act Regarding LUMRYZ Approval

Across the recent three months, 12 analysts have shared their insights on Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>), expressing a variety of opinions spanning from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $171.67, along with a high estimate of $205.00 and a low estimate of $120.00. Highlighting a 1.67% decrease, the current average has fallen from the previous average price target of $174.58. 
<img src="https://www.benzinga.com/files/images/story/2024/1729713693_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Jazz Pharmaceuticals among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$179.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$175.00</td>
<td>$174.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$205.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$140.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$202.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$140.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$166.00</td>
<td>$188.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$174.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$120.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$205.00</td>
<td>$208.00</td>
</tr>
<tr>
<td>Oren Livnat</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$154.00</td>
<td>$160.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Jazz Pharmaceuticals. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Jazz Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Jazz Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Jazz Pharmaceuticals's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/JAZZ/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Jazz Pharmaceuticals analyst ratings.</a>
<h2>Get to Know Jazz Pharmaceuticals Better</h2>
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
<h3>Unraveling the Financial Story of Jazz Pharmaceuticals</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Jazz Pharmaceuticals's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 6.95%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Jazz Pharmaceuticals's net margin is impressive, surpassing industry averages. With a net margin of 16.46%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Jazz Pharmaceuticals's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 4.52%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.49%, the company showcases effective utilization of assets.
Debt Management: Jazz Pharmaceuticals's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.54.
<h2>Analyst Ratings: What Are They?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

In-Depth Examination Of 12 Analyst Recommendations For Jazz Pharmaceuticals

RBC Capital analyst Gregory Renza maintains Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Outperform and raises the price target from $175 to $179.

Price Target

RBC Capital Maintains Outperform on Jazz Pharmaceuticals, Raises Price Target to $179

Jazz Pharmaceuticals Unit Terminates Lease Agreement With Stanford University, Effective June 30, 2025, Will Pay Lease Modification Fee, And Signs New Lease With Hudson Palo Alto Square To Occupy New Premises By July 1, 2025

Jazz Pharmaceuticals plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) revealed topline results from the Phase 3 clinical trial evaluating Zepzelca&nbsp;(lurbinectedin) in combination with the PD-L1 inhibitor Roche Holdings AG&#8217;s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) atezolizumab (Tecentriq) compared to atezolizumab alone when administered as a maintenance treatment for extensive-stage small cell lung cancer (ES-SCLC) following induction therapy with carboplatin, <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/n41328182/jazz-pharmaceuticals-announces-statistically-significant-overall-survival-and-progression-free-sur" rel="noreferrer noopener">etoposide and atezolizumab</a>.
The combination of&nbsp;Zepzelca and atezolizumab showed a statistically significant improvement in the primary endpoints of overall survival (OS) and progression-free survival (PFS), as assessed by an independent review facility (IRF), compared to treatment with atezolizumab alone.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40608567/jazz-and-hikma-accused-of-delaying-sleep-disorder-generic-drug-to-maintain-high-prices" rel="noreferrer noopener">Jazz And Hikma Accused Of Delaying Sleep Disorder Generic Drug To Maintain High Prices</a>.
&#8220;The results of the Phase 3 IMforte trial are highly encouraging and showed a statistically significant benefit for the&nbsp;Zepzelca&nbsp;and&nbsp;atezolizumab combination for extensive-stage small cell lung cancer patients receiving this treatment in the first-line maintenance setting,&#8221; said&nbsp;Rob Iannone, executive vice president, global head of research and development, and chief medical officer of Jazz Pharmaceuticals.
Iannone added, &#8220;These results demonstrate the potential of this regimen to delay disease progression and extend survival for patients with this aggressive disease.&#8221;
The company plans to submit a supplement marketing application in the U.S. in the first half of 2025 to support this combination in the first-line maintenance setting.
The combination was generally well-tolerated. The preliminary safety data in the ongoing trial were consistent with the known safety profiles of&nbsp;Zepzelca&nbsp;and atezolizumab, with no new safety signals observed in the combination arm.&nbsp;
Price Action: JAZZ stock is up 4.44% at $115.97 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41336511/ford-secures-supply-deal-with-lg-energy-for-electric-commercial-vans" target="_blank" rel="noreferrer noopener">Ford Secures Supply Deal With LG Energy For Electric Commercial Vans</a>.</li>
</ul>

Equities

Health Care

Movers

RHHBY

Jazz Pharmaceuticals' Zepzelca/Tecentriq Combo Regimen Can Potentially Delay Disease Progression, Extend Survival In Aggressive Form Of Lung Cancer

Jazz plans to submit supplemental New Drug Application in first half of 2025 for this combination therapy as a first-line maintenance treatment for ES-SCLC

Jazz Pharmaceuticals Reports Results For Zepzelca And Atezolizumab Combo In First-Line Maintenance For Small Cell Lung Cancer

Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) underwent analysis by 12 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $169.25, along with a high estimate of $205.00 and a low estimate of $120.00. This current average has decreased by 2.35% from the previous average price target of $173.33. 
<img src="https://www.benzinga.com/files/images/story/2024/1728061259_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Jazz Pharmaceuticals. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$175.00</td>
<td>$174.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$205.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$140.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$202.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$140.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$166.00</td>
<td>$188.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$174.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$120.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$205.00</td>
<td>$208.00</td>
</tr>
<tr>
<td>Oren Livnat</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$154.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Jeffrey Hung</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$150.00</td>
<td>$160.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Jazz Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Jazz Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Jazz Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Jazz Pharmaceuticals's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/JAZZ/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Jazz Pharmaceuticals analyst ratings.</a>
<h2>All You Need to Know About Jazz Pharmaceuticals</h2>
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
<h3>Jazz Pharmaceuticals's Financial Performance</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Positive Revenue Trend: Examining Jazz Pharmaceuticals's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 6.95% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 16.46%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Jazz Pharmaceuticals's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 4.52%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.49%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 1.54, Jazz Pharmaceuticals adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: What Are They?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing Jazz Pharmaceuticals: Insights From 12 Financial Analysts

RBC Capital analyst Gregory Renza maintains Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Outperform and raises the price target from $174 to $175.

RBC Capital Maintains Outperform on Jazz Pharmaceuticals, Raises Price Target to $175

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value investors use a variety of methods, including tried-and-true valuation metrics, to find these stocks.
Zacks has developed the innovative Style Scores system to highlight stocks with specific traits. For example, value investors will be interested in stocks with great grades in the &quot;Value&quot; category. When paired with a high Zacks Rank, &quot;A&quot; grades in the Value category are among the strongest value stocks on the market today.
One company to watch right now is Jazz Pharmaceuticals (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jazz#NASDAQ">JAZZ</a>). JAZZ is currently sporting a Zacks Rank of #2 (Buy) and an A for Value.
Investors should also note that JAZZ holds a PEG ratio of 1.05. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock&#39;s expected earnings growth rate. JAZZ&#39;s PEG compares to its industry&#39;s average PEG of 2.21. JAZZ&#39;s PEG has been as high as 1.44 and as low as 0.64, with a median of 1.05, all within the past year.
Value investors also love the P/S ratio, which is calculated by simply dividing a stock&#39;s price with the company&#39;s sales. This is a popular metric because sales are harder to manipulate on an income statement, so they are often considered a better performance indicator. JAZZ has a P/S ratio of 1.76. This compares to its industry&#39;s average P/S of 3.11.
Finally, investors will want to recognize that JAZZ has a P/CF ratio of 5.74. This metric focuses on a firm&#39;s operating cash flow and is often used to find stocks that are undervalued based on the strength of their cash outlook. JAZZ&#39;s P/CF compares to its industry&#39;s average P/CF of 11.35. Over the past year, JAZZ&#39;s P/CF has been as high as 43.45 and as low as 5.21, with a median of 7.66.
These are just a handful of the figures considered in Jazz Pharmaceuticals&#39;s great Value grade. Still, they help show that the stock is likely being undervalued at the moment. Add this to the strength of its earnings outlook, and we can clearly see that JAZZ is an impressive value stock right now.
<a href="https://www.zacks.com/stock/news/2344006/is-jazz-pharmaceuticals-jazz-stock-undervalued-right-now?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_2-2344006">To read this article on Zacks.com click here.</a>

Earnings

Mid Cap

Markets

Is Jazz Pharmaceuticals Stock Undervalued Right Now?

The well-known cannabis-based pharmaceutical drug Epidiolex, primarily used to treat childhood epilepsy, may offer relief to veterans suffering from Gulf War Illness (GWI), according to new research.
A new study on rats shows the potential of <a href="https://www.benzinga.com/topic/epidiolex">Epidiolex</a>, the FDA-approved cannabidiol (CBD) drug produced by Jazz Pharmaceuticals PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>)&#8217;s GW Pharmaceuticals, in addressing cognitive, mood and pain-related symptoms of GWI, a condition linked to chemical exposures during the 1990-1991 Gulf War.
The research, conducted by Chinese scientists, was first <a href="https://hemptoday.net/early-study-shows-epidiolex-may-have-potential-as-treatment-for-illness-in-veterans/">reported</a> by&nbsp;Hemp Today.
<h3 class="wp-block-heading">Cognitive And Pain Improvements Observed</h3>
The research, <a href="https://mmrjournal.biomedcentral.com/articles/10.1186/s40779-024-00563-2#Sec23">published</a> in Military Medical Research, reveals that long-term oral administration of CBD could alleviate cognitive impairments, mood disorders and chronic pain.
Rats treated with Epidiolex showed significant improvements in object recognition and memory retention, which are common areas of dysfunction in veterans with GWI. Additionally, CBD treatment helped ease anhedonia— the inability to experience pleasure— and reduced pain sensitivity.
<ul>
<li>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you&#8217;re serious about the business, you can&#8217;t afford to miss out.</li>
</ul>
GWI, which affects 25% to 32% of the 700,000 veterans who served in Operation Desert Storm, stems from exposure to environmental hazards like pesticides, burning oil wells and chemical agents.
Veterans experience chronic fatigue, muscle and joint pain, gastrointestinal issues, respiratory problems, cognitive dysfunction and headaches. The study highlights CBD's ability to target brain pathways linked to neuroinflammation and oxidative stress, both of which worsen GWI symptoms. In this manner, these findings add to the general notion of cannabis helping Veterans to overcome the consequences of war-related activity.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/22/08/28637449/thc-is-beneficial-for-ptsd-treatment-new-study-reveals">THC Is Beneficial For PTSD Treatment, New Study Reveals</a>
<h3 class="wp-block-heading">Veterans, Cannabis And War-Related Ailments</h3>
Unlike previous treatments such as curcumin or melatonin, Epidiolex proved effective at lower doses, reducing the risk of side effects. The 20 mg/kg dose used in rats equates to about 3.2 mg/kg for humans, offering a more efficient solution compared to other treatments. 
The research also notes that Epidiolex didn't impact motor function, confirming &#8220;an excellent safety profile even when taken long-term in low doses, with no observed harmful effects.&#8221;
Despite these promising results, the study emphasizes the need for further research, especially regarding potential drug interactions. 
While CBD offers hope for veterans with GWI, comprehensive clinical studies are essential before it can become a widespread treatment. 
This study, adds to the growing body of research on CBD showing medical uses for cannabis and war-related illnesses, such as <a href="https://www.benzinga.com/markets/cannabis/24/06/39381895/17-us-veterans-take-their-own-lives-everyday-heres-how-one-cannabis-company-is-trying-to-help">PTSD</a> and <a href="https://www.benzinga.com/24/07/39774432/new-study-shows-high-use-of-medical-cannabis-for-chronic-pain-and-arthritis-in-older-patients">chronic pain</a>.
<ul>
<li>Read Next: <a href="https://www.benzinga.com/markets/cannabis/24/06/39381895/17-us-veterans-take-their-own-lives-everyday-heres-how-one-cannabis-company-is-trying-to-help">17 US Veterans Take Their Own Lives Everyday, Here&#8217;s How One Cannabis Company Is Trying To Help</a></li>
</ul>
Cover: AI generated image

Cannabis

Economics

Media

FDA-Approved Cannabis-Based Drug Shows Promising Results As A Treatment For War Veterans: Study Finds Improvement In Cognitive, Mood, Pain-Related Symptoms

Jazz Pharmaceuticals Announced Updated Data, Including Median Progression-free Survival And Overall Survival Findings, From The Phase 2 Trial Of Zanidatamab, In Combination With Chemotherapy As First-line Treatment For HER2-expressing Advanced Or Metastatic Gastroesophageal Adenocarcinoma

Needham analyst Ami Fadia reiterates Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Buy and maintains $205 price target.

Reiteration

Needham Reiterates Buy on Jazz Pharmaceuticals, Maintains $205 Price Target

Analysts' ratings for Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) over the last quarter vary from bullish to bearish, as provided by 12 analysts.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Jazz Pharmaceuticals and provided 12-month price targets. The average target is $164.5, accompanied by a high estimate of $210.00 and a low estimate of $113.00. This current average has decreased by 3.24% from the previous average price target of $170.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1725904914_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Jazz Pharmaceuticals. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$140.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$202.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$140.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$166.00</td>
<td>$188.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$174.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$120.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$205.00</td>
<td>$208.00</td>
</tr>
<tr>
<td>Oren Livnat</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$154.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Jeffrey Hung</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$150.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$113.00</td>
<td>$117.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$210.00</td>
<td>$222.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Jazz Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Jazz Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Jazz Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Jazz Pharmaceuticals's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/JAZZ/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Jazz Pharmaceuticals analyst ratings.</a>
<h2>All You Need to Know About Jazz Pharmaceuticals</h2>
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
<h3>Understanding the Numbers: Jazz Pharmaceuticals's Finances</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Over the 3 months period, Jazz Pharmaceuticals showcased positive performance, achieving a revenue growth rate of 6.95% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Jazz Pharmaceuticals's net margin excels beyond industry benchmarks, reaching 16.46%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Jazz Pharmaceuticals's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 4.52%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Jazz Pharmaceuticals's ROA stands out, surpassing industry averages. With an impressive ROA of 1.49%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Jazz Pharmaceuticals's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.54.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Closer Look at 12 Analyst Recommendations For Jazz Pharmaceuticals

Cantor Fitzgerald analyst Charles Duncan reiterates Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Overweight and maintains $140 price target.

Cantor Fitzgerald Reiterates Overweight on Jazz Pharmaceuticals, Maintains $140 Price Target

Jazz Pharmaceuticals plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) today announced that the Company, along with its partners, will present five abstracts at the European Society for Medical Oncology (ESMO) Congress 2024 from September 13-17, 2024, in Barcelona, Spain. Presentations include data from trials of zanidatamab and Zepzelca&#xAE; (lurbinectedin).
New and updated data with longer follow-up, including overall survival findings, will be presented from an ongoing Phase 2 trial of zanidatamab, an investigational dual HER2-targeted bispecific antibody, in combination with chemotherapy for the first-line treatment of HER2-positive metastatic gastroesophageal adenocarcinoma (mGEA). Additional data from a Phase 2 study evaluating zanidatamab in combination with chemotherapy and bevacizumab as first-line treatment in HER2-positive metastatic colorectal cancer demonstrating encouraging antitumor activity will be presented as a mini-oral presentation at the congress.

Jazz Pharmaceuticals Highlights Zanidatamab and Zepzelca Cancer Trials at ESMO Congress

Axsome Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/axsm#NASDAQ">AXSM</a>) announced that the FDA has accepted its resubmitted new drug application (NDA) seeking approval for AXS-07 for the acute treatment of migraine.
A final decision from the regulatory body is expected on Jan. 31, 2025. The FDA has designated the NDA resubmission as a Class 2 resubmission.
Shares of AXSM were up 6.6% on Sept. 4 following the announcement of the news.
Year to date, shares of Axsome have rallied 20.1% against the industry&#39;s decrease of 0.9%.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/61/76711.jpg?v=1627352938" />
Image Source: Zacks Investment Research
The FDA issued a complete response letter to the first NDA for AXS-07 in April 2022 as it identified issues related to the chemistry, manufacturing and controls.
The NDA re-submission for AXS-07 for the acute treatment of migraine was completed during the second quarter of 2024. The FDA has not requested any additional safety or efficacy data for the NDA resubmission.
The NDA re-submission was earlier expected to be filed during the second half of 2023.
<h2>FDA Nod for AXS-07 to Diversify AXSM&#39;s Product Portfolio</h2>
Axsome currently has two marketed products in its commercial portfolio &ndash; Auvelity (AXS-05) for major depressive disorder and Sunosi (solriamfetol) for narcolepsy. A potential FDA nod for AXS-07 will diversify Axsome&#39;s commercial portfolio
Auvelity was launched in the United States in 2022 for the treatment of MDD, making it the first approved drug in the company&#39;s portfolio. The drug generated sales worth $118.4 million in the first half of 2024, up 172.8% year over year, owing to strong underlying demand.
Axsome&#39;s second marketed drug, Sunosi, is approved for treating narcolepsy. The company acquired U.S. rights to Sunosi from Jazz Pharmaceuticals (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jazz#NASDAQ">JAZZ</a>) in May 2022. It began selling Sunosi in the U.S. market in May 2022 and in certain international markets in November 2022.
Jazz received approval for Sunosi as a treatment for narcolepsy in 2019.
The acquisition of Sunosi from Jazz diversified Axsome&#39;s portfolio to two marketed drugs. In the first half of 2024, Sunosi&#39;s net product sales were $42.2 million, reflecting an increase of almost 35.2% year over year.
<h2>Zacks Rank &amp; Stocks to Consider</h2>
Axsome currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Krystal Biotech, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/krys#NASDAQ">KRYS</a>) and Fulcrum Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fulc#NASDAQ">FULC</a>), each sporting a Zacks Rank #1 (Strong Buy) at present.
In the past 60 days, estimates for Krystal Biotech&#39;s 2024 earnings per share have increased from $1.98 to $2.38. Earnings per share estimates for 2025 have improved from $4.33 to $7.31. Year to date, shares of KRYS have risen 50.6%.
KRYS&#39; earnings beat estimates in three of the trailing four quarters while missing on the remaining occasion, the average surprise being 49.9%.
In the past 60 days, estimates for Fulcrum Therapeutics&#39; 2024 loss per share have narrowed from $1.24 to 48 cents. Loss per share estimates for 2025 have narrowed from $1.71 to $1.51. Year to date, shares of FULC have jumped 22.2%.
FULC&#39;s earnings beat estimates in each of the trailing four quarters, the average surprise being 393.18%.
<a href="https://www.zacks.com/stock/news/2332290/fda-accepts-axsm-s-nda-resubmission-for-migraine-drug-stock-up?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2332290">To read this article on Zacks.com click here.</a>

Earnings Beats

Small Cap

AXSM

FULC

KRYS

FDA Accepts AXSM's NDA Resubmission for Migraine Drug, Stock Up

The notes will be general unsecured obligations of the Issuer and will accrue interest payable semiannually in arrears on&nbsp;March 15&nbsp;and&nbsp;September 15&nbsp;of each year, beginning on&nbsp;March 15, 2025, at a rate of&nbsp;3.125%&nbsp;per year. The notes will mature on&nbsp;September 15, 2030, unless earlier exchanged, redeemed or repurchased. Prior to&nbsp;June 15, 2030, the notes will be exchangeable only upon satisfaction of certain conditions and during certain periods, and thereafter, at any time until the close of business on the second scheduled trading day immediately preceding the maturity date.&nbsp;

Jazz Pharmaceuticals Launches $850M Senior Notes Offering And Kicks Off Share Buyback Strategy

Jazz Pharmaceuticals, together with its consolidated subsidiaries, expects to use a portion of the net proceeds to prepay up to approximately&nbsp;$350 million&nbsp;of the term loans outstanding under the credit agreement and the remainder for general corporate purposes.&nbsp;

Buybacks

Jazz Intends To Offer $850M Of Exchangeable Senior Notes Due 2030 In Private Offering; Plans Concurrent Ordinary Share Repurchases Up To $150M Of Its Ordinary Shares

Jazz Pharmaceuticals: Unexpected Wins Improve The Long-Term Outlook

Jazz Pharmaceuticals ( ($JAZZ) ) has provided an update. Jazz Pharmaceuticals is set to relocate its operations in Palo Alto following a new lease ...

Jazz Pharmaceuticals Relocates Operations to New Premises

Incannex Healthcare (IXHL) announced the appointment of Lou Barbato, M.D., as Chief Medical Officer, CMO, effective immediately. Dr. Barbato joins ...

Incannex appoints Barbato as Chief Medical Officer

Avadel soars after court rules in favor of FDA in Lumryz case with Jazz Pharma

H.C. Wainwright analyst Oren Livnat notes that the DC District Court ruled in Avadel's (AVDL) favor in the Jazz (JAZZ) vs. FDA and Avadel case, whe...

Court ruling removes 'last binary risk' for Avadel, says H.C. Wainwright

Jazz Pharmaceuticals (JAZZ) announced that eight abstracts presenting data from across its sleep portfolio were featured at the 37th annual Psych C...

Jazz Pharmaceuticals' Xywav shows efficacy in narcolepsy, idiopathic hypersomnia

Wells Fargo analyst Derek Archila downgraded Zymeworks (ZYME) to Equal Weight from Overweight with an unchanged price target of $13. The firm think...

Wells downgrades Zymeworks with zanidatamab approval priced in

Zymeworks: Turning The Tide With 2 Key Milestones For Zanidatamab

In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Jazz Pharmaceuticals (JAZZ – Research Report), with a price targ...

Barclays Sticks to Its Buy Rating for Jazz Pharmaceuticals (JAZZ)

Here are the major earnings after the close today

ACAD

ACLS

ADTN

AEVA

ALTO

AMPH

AMPY

AMRK

ANSS

APPS

ARAY

ARQT

ASPN

BBDC

BEIGF

BGNE

BIRD

DUOL

ENLC

GPMT

HCAT

HRTG

HUBS

IIPR

IONQ

IXHL

JOBY

KNTK

LAND

LILA

LILAK

LOPE

LUNMF

LYFT

MATV

MEOH

MKSI

MRMD

MTCH

NDLS

NEWT

NMIH

NVGS

ZYME

Press Releases

Jazz Pharmaceuticals to Participate in Upcoming September Investor Conferences

Jazz Pharmaceuticals Provides Update on Cannabidiol Oral Solution Phase 3 Trial in Japan in Treatment-Resistant Epilepsies

Offerings

Jazz Pharmaceuticals Announces Private Offering of $850 Million of Exchangeable Senior Notes due 2030 and Concurrent Ordinary Share Repurchases

Jazz Pharmaceuticals Announces Pricing of Private Offering of $850 Million of 3.125% Exchangeable Senior Notes due 2030 and Concurrent Ordinary Share Repurchases

Jazz Pharmaceuticals to Present New Data Demonstrating Improved Epilepsy Outcomes with Epidiolex®/Epidyolex® (cannabidiol) at the European Epilepsy Congress 2024

Jazz Pharmaceuticals to Present Advancements in Solid Tumor Oncology Research at ESMO 2024

Jazz Pharmaceuticals Presents Updated Phase 2 Data for Zanidatamab Demonstrating Increased mPFS in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ESMO 2024

Jazz Pharmaceuticals Announces Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca® (lurbinectedin) and Atezolizumab Combination in First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Jazz Pharmaceuticals to Report 2024 Third Quarter Financial Results on November 6, 2024

Jazz Pharmaceuticals Presents New Data at Psych Congress 2024 Confirming Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Benefits in Narcolepsy and Idiopathic Hypersomnia

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Catalent

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

Edgewise Therapeutics, Inc. - Common Stock

Edgewise Therapeutics

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

Jazz Pharmaceuticals

Jazz Pharmaceuticals (JAZZ) Opzioni

Jazz Pharmaceuticals (NASDAQ:JAZZ) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO